KR20030047873A - 클라리트로마이신 및 클라리트로마이신 중간체의 제조방법, 실질적으로는 옥심이 제거된 클라리트로마이신 및이를 포함하는 약학적 조성물 - Google Patents

클라리트로마이신 및 클라리트로마이신 중간체의 제조방법, 실질적으로는 옥심이 제거된 클라리트로마이신 및이를 포함하는 약학적 조성물 Download PDF

Info

Publication number
KR20030047873A
KR20030047873A KR1020027011330A KR20027011330A KR20030047873A KR 20030047873 A KR20030047873 A KR 20030047873A KR 1020027011330 A KR1020027011330 A KR 1020027011330A KR 20027011330 A KR20027011330 A KR 20027011330A KR 20030047873 A KR20030047873 A KR 20030047873A
Authority
KR
South Korea
Prior art keywords
clarithromycin
oxime
protective
silylated
erythromycin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020027011330A
Other languages
English (en)
Korean (ko)
Inventor
아브루토브일리야
리프쉬쯔이골
르위너엘리자베쓰
Original Assignee
테바 파마슈티컬 인더스트리즈 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 테바 파마슈티컬 인더스트리즈 리미티드 filed Critical 테바 파마슈티컬 인더스트리즈 리미티드
Publication of KR20030047873A publication Critical patent/KR20030047873A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C07F7/1872—Preparation; Treatments not provided for in C07F7/20
    • C07F7/1892—Preparation; Treatments not provided for in C07F7/20 by reactions not provided for in C07F7/1876 - C07F7/1888

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020027011330A 2000-02-29 2000-12-15 클라리트로마이신 및 클라리트로마이신 중간체의 제조방법, 실질적으로는 옥심이 제거된 클라리트로마이신 및이를 포함하는 약학적 조성물 Ceased KR20030047873A (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US18588800P 2000-02-29 2000-02-29
US60/185,888 2000-02-29
US18912000P 2000-03-14 2000-03-14
US60/189,120 2000-03-14
US21323900P 2000-06-22 2000-06-22
US60/213,239 2000-06-22

Publications (1)

Publication Number Publication Date
KR20030047873A true KR20030047873A (ko) 2003-06-18

Family

ID=27392028

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020027011330A Ceased KR20030047873A (ko) 2000-02-29 2000-12-15 클라리트로마이신 및 클라리트로마이신 중간체의 제조방법, 실질적으로는 옥심이 제거된 클라리트로마이신 및이를 포함하는 약학적 조성물

Country Status (15)

Country Link
US (3) US6617436B2 (cg-RX-API-DMAC7.html)
EP (1) EP1313486A1 (cg-RX-API-DMAC7.html)
JP (1) JP2004509062A (cg-RX-API-DMAC7.html)
KR (1) KR20030047873A (cg-RX-API-DMAC7.html)
AU (2) AU2001225787C1 (cg-RX-API-DMAC7.html)
CA (1) CA2401571A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ20023167A3 (cg-RX-API-DMAC7.html)
HR (1) HRP20020709A2 (cg-RX-API-DMAC7.html)
HU (1) HUP0302466A2 (cg-RX-API-DMAC7.html)
IL (1) IL151496A0 (cg-RX-API-DMAC7.html)
IS (1) IS6531A (cg-RX-API-DMAC7.html)
PL (1) PL366021A1 (cg-RX-API-DMAC7.html)
SK (1) SK13722002A3 (cg-RX-API-DMAC7.html)
WO (1) WO2001064224A1 (cg-RX-API-DMAC7.html)
YU (1) YU64202A (cg-RX-API-DMAC7.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20021999A3 (cs) * 1999-12-16 2003-02-12 Teva Pharmaceutical Industries Ltd. Způsob přípravy klaritromycinových polymorfních forem a nového polymorfu IV
CA2397092A1 (en) * 2000-01-11 2001-07-19 Teva Pharmaceutical Industries Ltd. Processes for preparing clarithromycin polymorphs
US6565882B2 (en) 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
WO2001064224A1 (en) * 2000-02-29 2001-09-07 Teva Pharmaceutical Industries Ltd. Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same
ATE432691T1 (de) * 2000-03-28 2009-06-15 Sandoz Ag Geschmackmaskierte granulierte teilchen
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US6541014B2 (en) 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
CA2533178C (en) 2003-07-21 2014-03-11 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
JP2006528185A (ja) 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
JP2006528190A (ja) 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
WO2005016311A1 (en) 2003-08-11 2005-02-24 Advancis Pharmaceutical Corporation Robust pellet
AU2004264356B2 (en) 2003-08-12 2011-01-27 Shionogi, Inc. Antibiotic product, use and formulation thereof
JP5686494B2 (ja) * 2003-08-29 2015-03-18 シオノギ インコーポレイテッド 抗生物質製剤、その使用法及び作成方法
EP1663169A4 (en) 2003-09-15 2010-11-24 Middlebrook Pharmaceuticals In ANTIBIOTICS, ITS USE AND FORMULATION
WO2006014427A1 (en) 2004-07-02 2006-02-09 Advancis Pharmaceutical Corporation Tablet for pulsed delivery
WO2007008537A2 (en) * 2005-07-07 2007-01-18 Elan Pharma International, Limited Nanoparticulate clarithromycin formulations
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8778924B2 (en) 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
US20090054634A1 (en) * 2007-08-09 2009-02-26 Vinod Kumar Kansal Process for the preparation of clarithromycin
CN102417532A (zh) * 2011-12-20 2012-04-18 浙江国邦药业有限公司 一种泰利霉素关键中间体5-德胺糖基-6-o-甲基红霉素的合成方法
CN102718821B (zh) * 2012-06-27 2014-12-03 浙江国邦药业有限公司 一种克拉霉素合成过程中甲基化反应以及甲基化试剂的回收套用方法
CN103880901A (zh) * 2012-12-23 2014-06-25 菏泽市方明制药有限公司 一种克拉霉素中间甲化物的制备方法
CN106905204B (zh) * 2017-02-24 2018-07-20 杭州新桂实业有限公司 一种克拉霉素合成过程中甲基化反应溶剂的回收套用方法
CN108117573A (zh) * 2017-12-26 2018-06-05 宁夏启元药业有限公司 4"-o-（三甲基硅）红霉素a 9-o-（1-乙氧基-1-甲基乙基）肟的合成方法

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US669236A (en) * 1900-02-16 1901-03-05 Frank M Garland Automatic machine-gun.
US3922379A (en) * 1973-12-17 1975-11-25 Abbott Lab Microencapsulation process
FR2473525A1 (fr) 1980-01-11 1981-07-17 Roussel Uclaf Nouvelles oximes derivees de l'erythromycine, leur procede de preparation et leur application comme medicaments
US4331803A (en) 1980-06-04 1982-05-25 Taisho Pharmaceutical Co., Ltd. Novel erythromycin compounds
EP0056195B1 (en) * 1980-12-25 1986-06-18 Fujitsu Limited Nonvolatile semiconductor memory device
JPS60214796A (ja) 1984-04-06 1985-10-28 Taisho Pharmaceut Co Ltd ６−０−メチルエリスロマイシン類の製法
JPS61103890A (ja) 1984-10-26 1986-05-22 Taisho Pharmaceut Co Ltd ６−０−メチルエリスロマイシンａ誘導体
DE3583799D1 (de) * 1985-01-11 1991-09-19 Abbott Lab Ltd Feste zubereitung mit langsamer freisetzung.
US4670549A (en) 1985-03-18 1987-06-02 Taisho Pharmaceutical Co., Ltd. Method for selective methylation of erythromycin a derivatives
US4640910A (en) 1985-11-12 1987-02-03 Abbott Laboratories Erythromycin A silylated compounds and method of use
US4672056A (en) 1985-11-12 1987-06-09 Abbott Laboratories Erythromycin A derivatives and method of use
KR960000434B1 (ko) 1986-12-17 1996-01-06 다이쇼 세이야꾸 가부시끼가이샤 에리스로마이신 a유도체 및 그의 제조 방법
US4808411A (en) * 1987-06-05 1989-02-28 Abbott Laboratories Antibiotic-polymer compositions
GB8721165D0 (en) 1987-09-09 1987-10-14 Beecham Group Plc Chemical compounds
JP2751385B2 (ja) 1988-05-19 1998-05-18 大正製薬株式会社 エリスロマイシンａオキシム及びその塩の製造方法
IT1246383B (it) * 1990-04-17 1994-11-18 Eurand Int Metodo per il mascheramento del sapore di farmaci
GB9120131D0 (en) * 1991-09-20 1991-11-06 Glaxo Group Ltd Medicaments
JP3265680B2 (ja) * 1992-03-12 2002-03-11 大正製薬株式会社 経口製剤用組成物
IL105155A (en) * 1992-04-24 1999-05-09 Astra Ab Combination of a substance with gastric acid secretion inhibiting effect and an acid degradable antibiotic
WO1993024109A1 (en) * 1992-06-04 1993-12-09 Smithkline Beecham Corporation Palatable pharmaceutical compositions
US5919489A (en) * 1995-11-01 1999-07-06 Abbott Laboratories Process for aqueous granulation of clarithromycin
US5756473A (en) 1995-11-21 1998-05-26 Abbott Laboratories 6-O-methyl erythromycin D and process for making
US5872229A (en) 1995-11-21 1999-02-16 Abbott Laboratories Process for 6-O-alkylation of erythromycin derivatives
US5705190A (en) * 1995-12-19 1998-01-06 Abbott Laboratories Controlled release formulation for poorly soluble basic drugs
US5998194A (en) * 1995-12-21 1999-12-07 Abbott Laboratories Polyketide-associated sugar biosynthesis genes
US5837829A (en) * 1996-04-02 1998-11-17 Abbott Laboratories 9-oximesilyl erythromycin a derivatives
US5719272A (en) 1996-04-02 1998-02-17 Abbott Laboratories 2'-protected 3'-dimethylamine, 9-etheroxime erythromycin A derivatives
US5808017A (en) 1996-04-10 1998-09-15 Abbott Laboratories Process for preparing erythromycin A oxime
AUPN969796A0 (en) * 1996-05-07 1996-05-30 F.H. Faulding & Co. Limited Taste masked liquid suspensions
PT915899E (pt) 1996-07-29 2004-11-30 Abbott Lab Preparacao da forma cristalina ii da eritromicina
US5858986A (en) 1996-07-29 1999-01-12 Abbott Laboratories Crystal form I of clarithromycin
US5844105A (en) 1996-07-29 1998-12-01 Abbott Laboratories Preparation of crystal form II of clarithromycin
US5972389A (en) * 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
US5945405A (en) 1997-01-17 1999-08-31 Abbott Laboratories Crystal form O of clarithromycin
US5864023A (en) 1997-02-13 1999-01-26 Abbott Laboratories 3'-N'oxide, 3'-n-dimethylamine, 9-oxime erythromycin a derivatives
US20050064033A1 (en) * 1997-04-11 2005-03-24 Notario Gerard F. Extended release formulations of erythromycin derivatives
US6551616B1 (en) * 1997-04-11 2003-04-22 Abbott Laboratories Extended release formulations of erythromycin derivatives
US6010718A (en) * 1997-04-11 2000-01-04 Abbott Laboratories Extended release formulations of erythromycin derivatives
ATE302597T1 (de) * 1997-06-06 2005-09-15 Depomed Inc Im magen verweilende orale dosierungsformen von wasserlöslichen arzneistoffen mit kontrollierter freisetzung
US6635280B2 (en) * 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
US5869098A (en) * 1997-08-20 1999-02-09 Fuisz Technologies Ltd. Fast-dissolving comestible units formed under high-speed/high-pressure conditions
US5929219A (en) * 1997-09-10 1999-07-27 Abbott Laboratories 9-hydrazone and 9-azine erythromycin derivatives and a process of making the same
US5852180A (en) 1997-11-17 1998-12-22 Abbott Laboratories Chemical synthesis of 6-O-alkyl erythromycin A
IL135792A0 (en) * 1997-12-01 2001-05-20 Abbott Lab 6-o-alkyl derivatives of erythronolide b
US5932710A (en) 1997-12-01 1999-08-03 Abbott Laboratories Process for preparing 6-O-alkyl-9-oxime erythromycin B
US5892008A (en) 1997-12-16 1999-04-06 Abbott Laboratories Process for the preparation of 6-O-methyl erythromycin a using 9-hydroxy erythromycin derivatives
KR100377159B1 (ko) 1998-09-09 2003-08-19 한미약품공업 주식회사 잔류 용매가 없는 클라리스로마이신의 결정형 2의 제조 방법
CA2282066C (en) * 1999-06-29 2010-09-07 Smithkline Beecham Corporation Methods of use of quinolone compounds against atypical upper respiratory pathogenic bacteria
DE19950781A1 (de) * 1999-10-21 2001-04-26 Knoll Ag Mehrteiliges Etikett für Durchdrückpackungen, seine Herstellung und Verwendung
KR100322313B1 (ko) * 1999-10-21 2002-02-06 민경윤 클라리스로마이신 결정형 2의 제조방법 및 이에 사용되는 클라리스로마이신 포르메이트
KR100336447B1 (ko) * 1999-11-24 2002-05-15 민경윤 클라리스로마이신의 개선된 제조방법
CZ20021999A3 (cs) * 1999-12-16 2003-02-12 Teva Pharmaceutical Industries Ltd. Způsob přípravy klaritromycinových polymorfních forem a nového polymorfu IV
CA2397092A1 (en) * 2000-01-11 2001-07-19 Teva Pharmaceutical Industries Ltd. Processes for preparing clarithromycin polymorphs
WO2001064224A1 (en) * 2000-02-29 2001-09-07 Teva Pharmaceutical Industries Ltd. Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same
DE60122791T2 (de) * 2000-03-15 2007-10-04 Hanmi Pharm. Co., Ltd. Verfahren zur Herstellung von Clarythromycin mit nicht pharmazeutischer Qualität
US6488962B1 (en) * 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
IN192748B (cg-RX-API-DMAC7.html) * 2000-08-29 2004-05-15 Ranbaxy Lab Ltd
ES2195727B1 (es) * 2001-07-05 2005-03-01 Ercros Industrial, S.A. Un procedimiento para la obtencion de claritromicina.
US6673369B2 (en) * 2001-08-29 2004-01-06 Ranbaxy Laboratories Limited Controlled release formulation
BR0308989A (pt) * 2002-04-03 2005-01-04 Ranbaxy Lab Ltd Formulações de claritromicina com biodisponibilidade aperfeiçoada e processo de preparação das mesmas
US20040043073A1 (en) * 2002-06-14 2004-03-04 Chih-Ming Chen Pharmaceutical compositions for drugs having pH-dependent solubility
US7063862B2 (en) * 2003-06-03 2006-06-20 Biokey, Inc. Pharmaceutical composition and method for treating
US20050053658A1 (en) * 2003-09-09 2005-03-10 Venkatesh Gopi M. Extended release systems for macrolide antibiotics

Also Published As

Publication number Publication date
IL151496A0 (en) 2003-04-10
AU2001225787C1 (en) 2006-09-21
US7101858B2 (en) 2006-09-05
PL366021A1 (en) 2005-01-24
WO2001064224A1 (en) 2001-09-07
JP2004509062A (ja) 2004-03-25
YU64202A (sh) 2005-03-15
SK13722002A3 (sk) 2003-08-05
US20030216556A1 (en) 2003-11-20
HUP0302466A2 (hu) 2003-11-28
US6617436B2 (en) 2003-09-09
HRP20020709A2 (en) 2004-12-31
CA2401571A1 (en) 2001-09-07
EP1313486A1 (en) 2003-05-28
US20010037015A1 (en) 2001-11-01
IS6531A (is) 2002-08-28
US20060205683A1 (en) 2006-09-14
AU2001225787B2 (en) 2005-12-08
AU2578701A (en) 2001-09-12
CZ20023167A3 (cs) 2003-10-15

Similar Documents

Publication Publication Date Title
US6617436B2 (en) Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same
AU2001225787A1 (en) Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same
KR101945324B1 (ko) 매크로라이드들 및 케톨라이드들과 이의 중간체들을 제조하는 공정들
EP1280535B1 (en) Processes for preparing clarithromycin polymorphs
EP0827965B1 (en) Synthesis of 9-deoxo- 9a-aza 11,12-deoxy- 9a-methyl-9a-homoerythromycin A 11,12- hydrogenorthoborate dihydrate
JP2003516999A (ja) クラリスロマイシン多型体の製法及び多型体ｉｖ
WATANABE et al. CHEMICAL MODIFICATION OF ERYTHROMYCINS. IX. 1) SELECTIVE METHYLATION AT THE C-6 HYDROXYL GROUP OF ERYTHROMYCIN A OXIME DERIVATIVES AND PREPARATION OF CLARITHROMYCIN
JP2782793B2 (ja) エリスロマイシンａ誘導体およびその製造方法
EP1304326B1 (en) Single-step process for preparing 7,16-deoxy-2-aza-10-o-cladinosil-12-o-desosaminil-4,5-dihydroxi-6-ethyl-3,5,9,11,13,15-hexamethylbicycle (11.2.1)hexadeca-1(2)-en-8-ona and obtaining a new form of 9-desoxo-9a-methyl-9a-aza-9a-homoerythromycin a
CN1205218C (zh) 选择性甲基化红霉素a衍生物的低成本方法
WO1999000125A1 (en) 9a-aza-3-ketolides, compositions containing such compounds and methods of treatment
ZA200206734B (en) Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same.
KR100804439B1 (ko) 에리트로마이신 유도체의 합성에서 아릴 티오이민을사용하는 방법
US20070043214A1 (en) Derivatives of azithromycin
JP3755664B2 (ja) クラリスロマイシンの製法
KR100467707B1 (ko) 클래리트로마이신의 제 ２결정형의 제조 방법
EP1444244B1 (de) Verfahren zur herstellung von desclarithromycin, sowie zwischenprodukte
WO2004007518A1 (en) Erythromycin a 9-o-pseudosaccharinyloxime derivatives and process for the preparation of clarithromycin using the same
WO2006064299A1 (en) Industrial process of clarithromycin associated with controlled level of side products
KR20010010096A (ko) 클라리스로마이신의 제조방법 및 이에 사용되는 중간체
JPH0764867B2 (ja) ６−ｏ−メチルエリスロマイシンａ誘導体およびその製造方法
JPH10245392A (ja) デスマイコシン誘導体およびマイカミノシルタイロノライド誘導体
EP1633764A1 (en) Q-alkyl macrolide and azalide derivatives and regioselective process for their preparation
MXPA01009379A (en) Single-step process for preparing 7,16-deoxy-2-aza-10-o-cladinosil-12-o-desosaminil-4, 5-dihydroxi-6-ethyl-3,5,9,11,13,15-hexamethylbicycle (11.2.1)hexadeca-1(2)-en-8-ona and obtaining a new form of 9-desoxo-9a-methyl-9a-aza-9a-homoerythromycin a
KR19990085779A (ko) 6-0-메틸 에리트로마이신의 제조방법

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000